845614-11-1 Usage
Description
[4-(3-Fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-Methylsulfonyl-2-[((S)-2,2,2-trifluoro-1-methylethyl)oxy]phenyl]methanone, also known as Bitopertin, is a complex organic compound with a unique molecular structure. It is a potent and noncompetitive glycine reuptake inhibitor (GRI) that has been developed for the treatment of schizophrenia.
Uses
Used in Pharmaceutical Industry:
Bitopertin is used as an investigational agent for the treatment of schizophrenia. It functions as a glycine reuptake inhibitor, which helps to modulate the levels of glycine in the brain, a crucial component for the proper functioning of the NMDA receptor. This modulation is believed to have a positive impact on the symptoms of schizophrenia, making it a promising candidate for further research and development in the pharmaceutical industry.
Check Digit Verification of cas no
The CAS Registry Mumber 845614-11-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,4,5,6,1 and 4 respectively; the second part has 2 digits, 1 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 845614-11:
(8*8)+(7*4)+(6*5)+(5*6)+(4*1)+(3*4)+(2*1)+(1*1)=171
171 % 10 = 1
So 845614-11-1 is a valid CAS Registry Number.
845614-11-1Relevant articles and documents
Bitopertin synthetic method and intermediate
-
, (2018/03/26)
The present invention discloses a new synthesis method and intermediates of Bitopertin. According to the Bitopertin synthesis method, 5-methylsulfonyl-2-[(1S)-2,2,2-trifluoro-1-methylethoxy]benzoic acid is adopted as a raw material, and continuous multi-step operations such as chlorination, acylation, deprotection, condensation and re-crystallization are subjected to performed to obtain the Bitopertin, wherein the intermediates in each step do not require further purification, and the total yield can achieve more than or equal to 80%.
SYNTHESIS OF GLYT-1 INHIBITORS
-
Page/Page column 10-11, (2008/12/08)
The present invention relates to a process for preparation of a compound of formula I wherein Het, R1, R2, R3, and n are as defined herein and pharmaceutically acceptable acid addition salts thereof, which comprises reacting a compound of formula 21 with a compound of formula 8 to obtain a compound of formula 11 and coupling the compound of formula 11 in the presence of a coupling reagent or the corresponding acid halogenide with a compound of formula 15 to obtain a compound of formula I.